| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 68084-0399-11 | 68084-0399 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan 24, 2012 | Jul 31, 2019 | No Longer Used |
| 71837-5843-05 | 71837-5843 | SARGRAMOSTIM | Leukine | 250.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | Intravenous, Subcutaneous | Sep 1, 2023 | In Use | |
| 16714-0201-10 | 16714-0201 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 27, 2021 | In Use | |
| 00703-7871-01 | 00703-7871 | Granisetron Hydrochloride | Granisetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Dec 31, 2007 | Aug 31, 2010 | No Longer Used | ||
| 71205-0908-00 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 16, 2021 | In Use | |
| 00378-8172-91 | 00378-8172 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Nov 1, 2011 | May 31, 2016 | No Longer Used |
| 82448-0050-18 | 82448-0050 | Nirogacestat | OGSIVEO | 50.0 mg/1 | Ancillary Therapy | Miscellaneous Agent | Ɣ Secretase Inhibitor | Oral | Nov 27, 2023 | In Use | |
| 51655-0016-87 | 51655-0016 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 21, 2022 | In Use | |
| 00006-4045-41 | 00006-4045 | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | GARDASIL | 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Jun 8, 2006 | In Use | |
| 63739-0495-43 | 63739-0495 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 22, 2010 | Sep 30, 2012 | In Use |
| 66658-0112-06 | 66658-0112 | Palifermin | Kepivance | 6.25 mg/1.2mL | Ancillary Therapy | Epithelial Growth Factor | Keratinocyte Growth Factor/rHuKGF | Intravenous | Dec 15, 2009 | Apr 20, 2023 | No Longer Used |
| 68071-1987-02 | 68071-1987 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 23, 2017 | In Use | |
| 00409-3414-01 | 00409-3414 | Metoclopramide | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Feb 2, 2006 | In Use | |
| 55513-0823-01 | 55513-0823 | Epoetin alfa | Epogen | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Mar 3, 1997 | Jul 31, 2010 | No Longer Used | |||
| 70121-1569-07 | 70121-1569 | Filgrastim | RELEUKO | 300.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb 25, 2022 | In Use | |
| 55513-0478-20 | 55513-0478 | Epoetin alfa | Epogen | 20000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Apr 14, 2025 | In Use | ||
| 66336-0793-10 | 66336-0793 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
| 54569-6168-01 | 54569-6168 | Ondansetron, ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 9, 2016 | In Use | |
| 57237-0078-50 | 57237-0078 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 30, 2024 | In Use | |
| 58118-0458-09 | 58118-0458 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | Jun 26, 2017 | No Longer Used |
| 51991-0065-97 | 51991-0065 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 1, 2020 | May 2, 2020 | No Longer Used | |
| 70121-1568-07 | 70121-1568 | Filgrastim | RELEUKO | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb 25, 2022 | In Use | |
| 63459-0910-17 | 63459-0910 | tbo-filgrastim | Granix | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Mar 2, 2015 | In Use | |
| 71205-0908-55 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 16, 2021 | In Use | |
| 51662-1288-01 | 51662-1288 | METOCLOPRAMIDE | METOCLOPRAMIDE | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Sep 22, 2018 | In Use |
Found 11765 results — Export these results
Home